RARE - CIK 0001515673
Ultragenyx Pharmaceutical Inc. (RARE) reported revenue of $673.00M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $673.00M | +20.2% |
| FY 2024 | $560.00M | +29.0% |
| FY 2023 | $434.00M | +19.5% |
| FY 2022 | $363.33M | +3.4% |
| FY 2021 | $351.41M | +29.7% |
| FY 2020 | $271.03M | +161.3% |
| FY 2019 | $103.71M | +101.4% |
| FY 2018 | $51.49M | +1871.5% |
| FY 2017 |
Ultragenyx Pharmaceutical Inc. (RARE) reported revenue of $673.00M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2016 and fiscal 2025, Ultragenyx Pharmaceutical Inc.'s revenue grew from $133.00K to $673.00M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $2.61M |
| +1863.9% |
| FY 2016 | $133.00K | - |